Director Eugene Williams of ProMIS Neurosciences Inc. filed a statement of changes in beneficial ownership on November 3, 2026, reporting a purchase of common shares on October 30, 2026.

Key Highlights

  • Reporting person: Eugene Williams, a director of ProMIS Neurosciences Inc. (NASDAQ:PMN)
  • Transaction: Purchase (transaction code P) of 1,316 common shares on October 30, 2026
  • Price paid: $3.99 per share
  • Resulting ownership: 13,713 common shares held directly following the transaction
  • Filing date: November 3, 2026, signed by Max A. Milbury as attorney-in-fact for Eugene Williams

Director Williams Adds to ProMIS Neurosciences Position in October 2026

According to the filing, Eugene Williams, identified as a director of ProMIS Neurosciences Inc., acquired 1,316 common shares on October 30, 2026, at a price of $3.99 per share. The transaction is coded "P," indicating an open-market purchase. ProMIS Neurosciences is a neuroscience-focused company listed on the Nasdaq exchange under the ticker PMN and incorporated in Canada, with its registered address at Suite 200, 1920 Yonge Street, Toronto, Ontario.

Following this acquisition, the filing reports that Williams directly holds 13,713 common shares. No derivative securities were reported in Table II of the filing, and no Rule 10b5-1 plan box was checked, meaning the filing does not indicate the purchase was made pursuant to a pre-established trading plan. The filing was submitted by Max A. Milbury acting as attorney-in-fact on behalf of Eugene Williams.

What Was Disclosed

Director Eugene Williams reported an open-market purchase of 1,316 common shares of ProMIS Neurosciences Inc. at $3.99 per share on October 30, 2026, bringing his total direct beneficial ownership to 13,713 common shares, according to the filing.